Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

NCT03054038 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

22

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Non-Small Cell Lung Carcinoma

Interventions

DRUG: Afatinib
BIOLOGICAL: Necitumumab
OTHER: Laboratory Biomarker Analysis

Sponsor

Vanderbilt-Ingram Cancer Center

Collaborators

[object Object]
[object Object]